Agile And Differentiated, AlphaMab Riding High In China Biotech Boom
This article was originally published in PharmAsia News
AlphaMab is attracting attention as the Suzhou-based biotech has filed China's first PD-L1 antibody, giving it a lead over larger and multinational competitors. The venture’s winning strategy lies in staying ahead of the curve, CEO Xu Ting told PharmAsia News in an exclusive interview.
Register for our free email digests: